APA

Greenberg H. E., Gottesdiener K., Huntington M., Wong P., Larson P., Wildonger L., Gillen L., Dorval E. & Waldman S. A. (20001222). A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. : Journal of clinical pharmacology.

Chicago

Greenberg H E, Gottesdiener K, Huntington M, Wong P, Larson P, Wildonger L, Gillen L, Dorval E and Waldman S A. 20001222. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. : Journal of clinical pharmacology.

Harvard

Greenberg H. E., Gottesdiener K., Huntington M., Wong P., Larson P., Wildonger L., Gillen L., Dorval E. and Waldman S. A. (20001222). A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. : Journal of clinical pharmacology.

MLA

Greenberg H E, Gottesdiener K, Huntington M, Wong P, Larson P, Wildonger L, Gillen L, Dorval E and Waldman S A. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. : Journal of clinical pharmacology. 20001222.